Arthritis Care & Research · 11 Nov 2026
Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index
Alice Horisbergerh-index 13, Youngmin Kim, Jeong Yee, Jacob J.E. Koopman, Sindhu R Johnson, Alí Duarte‐García, Zahi Touma, Marta Mosca, Karen H. Costenbaderh-index 28
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Objective SLE is often preceded by a preclinical phase in which autoantibodies and other biomarkers are detectable, offering an opportunity to identify at‐risk individuals for early monitoring and testing interventions to halt progression. To inform an effort to develop SLE risk‐stratification criteria, we conducted a scoping review of longitudinal human studies of biomarkers measured before SLE onset. Methods Following PRISMA‐ScR, we searched three databases and used a Population, Exposure, Comparator, Outcome framework to select longitudinal studies in which biomarkers were measured before an incident diagnosis or classification of SLE. Study characteristics, biomarkers, and outcomes were extracted from included studies. Results We included 59 original studies and two meta‐analyses including heterogeneous at‐risk populations, in which the proportion progressing to SLE varied widely. Most evidence concerned conventional serological markers, whereas interferon and cytokine signatures, proteomic panels, and genetic risk scores were examined in fewer, recent cohorts. Few biomarkers were studied across multiple populations or with comparable follow‐up, outcome definitions, and analytic methods, and most associations came from single studies without external validation. Longitudinal biomarker trajectories before onset were rarely characterized, and non‐European populations were under‐represented. Conclusion his review maps the breadth of candidate biomarkers associated with the risk of developing SLE and the heterogeneity of the evidence supporting them. Building a clinically useful SLE risk‐stratification index will need a shared definition of the at‐risk state, and prospective studies that follow biomarkers over time, in populations from broader geographical regions.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Karen H. Costenbader has the highest h-index among the authors (28).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.